Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy☆
Section snippets
Subjects
We prospectively recruited patients with various macular disorders, including CNV due to age-related macular degeneration, myopic CNV, idiopathic CNV, polypoidal choroidal vasculopathy, and central serous chorioretinopathy who were scheduled for the first PDT. Photodynamic therapy was carried out in the patients with symptomatic polypoidal choroidal vasculopathy due to serous neurosensory retinal detachment, serous pigment epithelial detachment, or subretinal hemorrhage, and in patients with
Patient demographics and pdt application
A total of 17 eyes from 17 patients (12 male, 5 female) who were scheduled for PDT were recruited (Table 1). The mfERG recordings were performed in all patients before PDT, and at 4 days, 2 weeks, and 1 month after PDT. An example of a patient's mfERG recordings is displayed in Figure 1. The mean age of the patients was 50.5 years (range, 29 to 75). Four patients (23.5%) had a diagnosis of idiopathic CNV, four (23.5%) had myopic CNV, four (23.5%) had polypoidal choroidal vasculopathy, three
Discussion
Transient visual disturbances or severe visual losses are some of the adverse events that may occur early after PDT. In the VIP study, 10 (4.4%) of the 225 patients suffered severe visual loss (loss of visual acuities of at least 4 lines or 20 letters) within 7 days after PDT, in which 6 (2.6%) had no obvious causes or findings on clinical examination.3 Subjective visual disturbances were also reported in 42% of patients in the verteporfin-treated group.3 Similar transient visual disturbances
Supplementary files
References (28)
- et al.
Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin
Am J Ophthalmol
(2002) - et al.
Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin
Am J Ophthalmol
(2002) - et al.
Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy
Am J Ophthalmol
(2003) - et al.
Theoretical investigation of the role of choriocapillaris blood flow in the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
Am J Ophthalmol
(2001) - et al.
Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization
Am J Ophthalmol
(2002) - et al.
The field topography of ERG components in man—I. The photopic luminance response
Vision Res
(1992) - et al.
The multifocal ERGunmasked by selective cross-correlation
Vision Res
(2002) - et al.
Evaluation of successful macular hole surgery by optical coherence tomography and multifocal electroretinography
Am J Ophthalmol
(2002) - et al.
Influence of photodynamic therapy in choroidal neovascularization of focal retinal function assessed with the multifocal electroretinogram and perimetry
Ophthalmology
(2002) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trialsTAP report 1
Arch Ophthalmol
(1999)
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trialsTAP report 2
Arch Ophthalmol
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degenerationtwo-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: verteporfin in photodynamic therapy report 2
Am J Ophthalmol
Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin1-year results of a randomized clinical trial. VIP report no. 1
Ophthalmology
Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia2-year results of a randomized clinical trial. VIP report no. 3
Ophthalmology
Cited by (100)
Longitudinal multimodal functional macular analysis after half-dose photodynamic therapy for central serous chorioretinopathy
2022, Photodiagnosis and Photodynamic TherapyCitation Excerpt :Oiwa et al. also found an improvement in the retinal electrical response using half-dose PDT in 14 eyes of 13 patients with chronic CSC, followed for 12 months [28]. Several authors have described an early transient retinal functional impairment using full-dose PDT (6 mg/m2) for myopic, idiopathic and age-related macular degeneration choroidal neovascularization and polypoidal choroidal vasculopathy [25,32,33]. These changes seemed to attenuate at 2 and 4 weeks after treatment, recovering to a near-normal retinal function 1 month post-treatment.
A pH-responsive silica–metal–organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries
2020, Journal of Controlled ReleaseCitation Excerpt :The biocompatibility of SMOF after subretinal injection was evaluated by electroretinography (ERG) of the retina. ERG evaluates the light-induced electronic response of the eye, and any damage to the RPE or retina result in alternations in ERG recording [35–37]. PBS and Ai14 RNP-loaded SMOF-ATRA were injected to the eyes of C57BI/6 mice.
Drugs Used in Ophthalmology
2020, Drug-Induced Ocular Side Effects, Eigtht EditionA Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy
2016, American Journal of Ophthalmology
- ☆
Biosketches and/or additional material at www.ajo.com.